Trending at Lumira Ventures

Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion also reported preclinical …

Lumira Portfolio Company, G1 Therapeutics, Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

Altamash Hashmi G1 Therapeutics, Portfolio News

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ (trilaciclib) administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in …

Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, June 7, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research. “Isabelle brings deep oncology research experience, including …

Fusion Pharmaceuticals, A Lumira Portfolio Company, Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, June 2, 2021: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing …

Lumira Portfolio Company, enGene, Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial

Altamash Hashmi enGene, Portfolio News

BOSTON and MONTRÉAL, May 27, 2021: enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 …

Fusion Pharmaceuticals, Lumira Portfolio Company, Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (Pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as …

Lumira portfolio company, G1 Therapeutics, Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)

Altamash Hashmi G1 Therapeutics, Portfolio News

– PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

Altamash Hashmi G1 Therapeutics, Portfolio News

– Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Laboratory Values, and Use of Supportive Care Interventions – – Compared with Placebo, Administering COSELA Prior …